Drug
Pirtobrutinib
Pirtobrutinib: highest development phase Phase 1/2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pirtobrutinib NCT03740529 | Phase 1/2 | Chronic Lymphocytic Leukemia |
Latest
No recent events.
Follow Pirtobrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.